Abstract
Background: Over 200 million people have chronic obstructive pulmonary disease (COPD) worldwide. The number of disease-year equivalents and deaths attributable to COPD are high.Guidelines for the pharmacological treatment of the disease recommend an individualized step-up approach in which treatment is intensified when results are unsatisfactory.
Objective: Our objective was to present a systematic review of the cost effectiveness of pharmacological maintenance treatment for COPD and to discuss the methodological strengths and weaknesses of the studies.
Methods: A systematic literature search for economic evaluations of drug therapy in COPD was performed inMEDLINE, EMBASE, the Economic Evaluation Database of the UK NHS (NHS-EED) and the European Network of Health Economic Evaluation Databases (EURONHEED). Full economic evaluations presenting both costs and health outcomes were included.
Results: A total of 40 studies were included in the review.Of these, 16 were linked to a clinical trial, 14 usedMarkovmodels, eight were based on observational data and two used a different approach. The few studies on combining short-acting bronchodilators were consistent in finding net cost savings compared with monotherapy. Studies comparing inhaled corticosteroids (ICS) with placebo or no maintenance treatment reported inconsistent results. Studies comparing fluticasone with salmeterol consistently found salmeterol to be more cost effective. The cost-effectiveness studies of tiotropium versus placebo, ipratropium or salmeterol pointed towards a reduction in total COPD-related healthcare costs for tiotropium in many but not all studies. All of these studies reported additional health benefits of tiotropium. The cost-effectiveness studies of the combination of inhaled long-acting β2-agonists and ICS all report additional health benefits at an increase in total COPD-related costs in most studies. The cost-per-QALY estimates of this combination treatment vary widely and are very sensitive to the assumptions on mortality benefit and time horizon.
Conclusions: The currently available economic evaluations indicate differences in cost effectiveness between COPD maintenance therapies, but for a more meaningful comparison of results it is important to improve the consistency with respect to study methodology and choice of comparator.
Similar content being viewed by others
References
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2010 [online]. Available from URL: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html [Accessed 2010 Apr 16]
Wouters EF. Chronic obstructive pulmonary disease: 5. Systemic effects of COPD. Thorax 2002; 57: 1067–70
Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006; 130: 1117–28
Stahl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3: 56
Jenkins C, Rodriguez-Roisin R. Quality of life, stage severity and COPD. Eur Respir J 2009; 33: 953–5
Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96: 700–8
Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398S–401S
Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J 2011; 37 (3): 508–15
Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–22
Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698–702
Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387–95
Oostenbrink JB, Rutten-van Mölken MPMH. Resource use and risk factors in high cost exacerbations of COPD. Respir Med 2004; 98: 883–91
O’Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007; 61: 1112–20
Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416–69
World Health Organization. Chronic obstructive pulmonary disease [fact sheet no. 315]. Geneva: WHO, 2008 [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs315/en/ [Accessed 2010 Jun 1]
Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries: part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis 2008; 12: 703–8
Luijben AHP, Kommer GJ. Time-trends and future: part of the public health status and forecast report [report no.270061008; in Dutch]. Bilthoven: RIVM, 2010 [online]. Available from URL: http://www.vtv2010.nl/deelrapporten/tijd–toekomst/ [Accessed 2011 Nov 8]
US Department of Health and Human Services. National Institutes of Health, National Heart Lung and Blood Institute. Morbidity and mortality: 2007 chart book on cardiovascular, lung and blood diseases. 2007 Jun [online]. Available from URL: http://www.nhlbi.nih.gov/resources/docs/07-chtbk.pdf [Accessed 2011 Nov 8]
European Lung Foundation, European Respiratory Society. European Lung White Book. Lausanne: ERS, 2003
Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46
Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19 (6): 623–42
D’Souza AO, Smith MJ, Miller LA, et al. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest 2006; 129: 1693–708
Rutten-van Mölken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 630–4
Halpin DMG. Health economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 227–33
Dal Negro R. Optimizing economic outcomes in the management of COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 1–10
Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J Chron Obstruct Pulmon Dis 2008; 3: 71–88
Toy EL, Gallagher KF, Stanley EL, et al. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010; 7: 214–28
Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635–41
Jones PW, Wilson K, Sondhi S. Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir Med 2003; 97: 20–6
Friedman M, Menjoge SS, Anton SF, et al. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004; 22 (11): 741–9
Oostenbrink JB, Rutten-van Mölken MPMH, Al MJ, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241–9
Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008; 63: 962–7
Rutten-van Mölken MPMH, van Doorslaer EKA, Jansen MCC, et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 975–82
van den Boom G, Rutten-van Mölken MPMH, Molema J, et al. The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease: results of the DIMCA program. Am J Respir Crit Care Med 2001; 164: 2057–66
Ayres JG, Price MJ, Efthimiou J. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebocontrolled trial. Respir Med 2003; 97: 212–20
Briggs AH, Lozano-Ortega G, Spencer S, et al. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value Health 2006; 9: 227–35
van der Palen J, Monninkhof E, van der Valk P, et al. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease. Thorax 2006; 61: 29–33
Löfdahl CG, Ericsson A, Svensson K, et al. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics 2005; 23 (4): 365–75
Briggs AH, Glick HA, Lozano-Ortega G, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J 2010; 35: 532–9
Rutten-van Mölken MP, van Nooten FE, Lindemann M, et al. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics 2007; 25 (8): 695–711
Collet JP, Ducruet T, Haider S, et al. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease. Can Respir J 2001; 8: 27–33
Dalal AA, St Charles M, Petersen HV, et al. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 mg versus salmeterol in severe COPD patients. Int J Chron Obstruct Pulmon Dis 2010; 5: 179–87
Mittmann N, Hernandez P, Mellström C, et al. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives. Pharmacoeconomics 2011; 29 (5): 403–14
Hogan TJ, Geddes R, Gonzalez ER. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin Ther 2003; 25: 285–97
Oostenbrink JB, Rutten-van Molken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8: 32–46
Schramm W, Haake D, Brandt A. Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease. Praxis (Bern 1994) 2005; 94: 1803–10
Maniadakis N, Tzanakis N, Fragoulakis V, et al. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr Med Res Opin 2006; 22: 1599–607
Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007; 8: 123–35
Gani R, Griffin J, Kelly S, et al. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010; 19: 68–74
Naik S, Kamal KM, Keys PA, et al. Evaluating the costeffectiveness of tiotropiumversus salmeterol in the treatment of chronic obstructive pulmonary disease. Clinico Economics Outcomes Res 2010; 2: 25–36
Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116: 325–31
Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619–37
Dal Negro R, Eandi M, Pradelli L, et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients. Int J Chronic Obstruct Pulmon Dis 2007; 2: 169–76
Chuck A, Jacobs P, Mayers I, et al. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease. Can Respir J 2008; 15: 437–43
Earnshaw SR, Wilson MR, Dalal AA, et al. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med 2009; 103: 12–21
Oba Y. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care 2009; 15: 226–32
Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011; 105: 1635–47
Benayoun S, Ernst P, Suissa S. The impact of combined inhaled bronchodilator therapy in the treatment of COPD. Chest 2001; 119: 85–92
Gagnon YM, Levy AR, Spencer MD, et al. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. Respir Med 2005; 99: 1534–45
Akazawa M, Stearns SC, Biddle AK. Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims. Health Serv Res 2008; 43: 2164–82
Akazawa M, Hayflinger DC, Stanford RH, et al. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care 2008; 14: 438–48
Onukwugha E, Mullins CD, DeLisle S. Using costeffectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system. Value Health 2008; 11: 980–8
Jubran A, Gross N, Ramsdell J, et al. Comparative costeffectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. Chest 1993; 103: 678–84
Neyt M, Devriese S, Thiry N, et al. Tiotropium’s costeffectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions. BMC Pulm Med 2010; 10: 47
Dalal AA, Roberts MH, Petersen HV, et al. Comparative cost-effectiveness of a fluticasone-proprionate/salmeterol combination versus anticholinergics as maintenance therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011; 6: 13–22
Lee KH, Phua J, Lim TK. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Respir Med 2006; 100: 2190–6
Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc 2007; 82: 575–82
Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093–103
Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009; 34: 10–2
Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34: 13–6
Van der Valk P, Monninkhof E, Van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166: 1358–63
Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89
Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62: 1081–7
Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154–61
Rabe KF, Bateman ED, O’Donnell D, et al. Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563–71
Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685–94
Mapel DW, Schum M, Lydick E, et al. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics 2010; 28 (9): 733–49
Verhage TL, Heijdra YF, Molema J, et al. Adequate patient characterization in COPD: reasons to go beyond GOLD classification. Open Respir Med J 2009; 3: 1–9
Paterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the MeasureYour MedicalOutcome Profile (MYMOP),Medical Outcomes Study 6-item General Health Survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res 2000; 9: 521–7
Goossens LM, Nivens MC, Sachs P, et al. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respir Med 2011; 105 (8): 1195–202
Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589–93
Shiroiwa T, Sung Y, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost-effectiveness? Health Econ 2009; 19: 422–37
Harper R, Brazier JE, Waterhouse JC, et al. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax 1997; 52: 879–87
Stavem K. Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 1999; 8: 45–54
Ringbaek T, Brondum E, Martinez G, et al. Euro QoL in assessment of the effect of pulmonary rehabilitation COPD patients. Respir Med 2008; 102: 1563–7
Petrillo J, van Nooten F, Jones P, et al. Utility estimation in chronic obstructive pulmonary disease: a preference for change? Pharmacoeconomics 2011; 29 (11): 917–32
Meguro M, Jones PW. Elicitation of utility weights for a COPD specific preference measure [abstract]. Am J Respir Crit Care Med 2006; 3: A488
Ståhl E, Lindberg A, Jansson S-A, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3: 56
Barton GR, Sach TH, Jenkinson C, et al. Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health Qual Life Outcomes 2008; 6: 51
Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003 Jun; 41: 46–53s
Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press, 2005
Acknowledgements
Maureen Rutten-van Mölken and Lucas Goossens do not have a financial interest in any COPD medication. As university employees they have performed cost-effectiveness studies for multiple pharmaceutical companies. Maureen Rutten-van Mölken has received speaker fees from multiple pharmaceutical companies that are active in the treatment of COPD. Maureen Rutten-van Mölken and Lucas Goossens have both read and discussed the papers in the review and jointly wrote this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rutten-van Mölken, M.P., Goossens, L.M. Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease. PharmacoEconomics 30, 271–302 (2012). https://doi.org/10.2165/11589270-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11589270-000000000-00000